Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SELECT MDS-1: Tamibarotene + Azacitidine in HR-MDS
NCT04797780Phase 3Terminated
- Sponsor
- Syros Pharmaceuticals
- Start
- Feb 2021
- Primary completion
- Nov 2024
- Modality
- Orthosteric Ligands
- Countries
- 13
01
Overview
Phase 3, randomised, double-blind trial in myelodysplastic syndromes (MDS) comparing Tamibarotene + Azacitidine with Placebo + Azacitidine (2 arms). Primary endpoint: Percentage of Participants With Complete Remission up to 45 months. Started Feb 2021; status: terminated.
02
Drugs
tamibarotene
03
Conditions
myelodysplastic syndromes (MDS)
Beyond the preview
Go deeper on NCT04797780.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04797780.